Novel CDK 4/6 Inhibitor Proves Mettle at HR+/HER2

The investigational cyclin-dependent kinase (CDK) 4/6 inhibitor dalpiciclib could be a new treatment option for patients with HR-positive/HER2-negative advanced breast…

2 months ago

RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers

The RET inhibitor selpercatinib (Retevmo) exhibited clinical activity in almost half of patients with non-lung/non-thyroid cancers associated with RET gene…

3 months ago